PMID: 28525227Jan 1, 2016Paper

Management of chronic hepatitis C in 2016

Revue médicale de Bruxelles
C Moreno, D Domngang

Abstract

Chronic hepatitis C virus infection is a major public health problem. It is estimated that 15 to 35 % of infected patients will develop cirrhosis after a period of 30 years. Fibrosis stage must be evaluated in all hepatitis-C-infected patients, even in patients with normal serum transaminases. Non-invasive methods for the evaluation of liver fibrosis have been developed, mainly serum markers and transient elastography or Fibroscan'Ñ¢. The goal of therapy is to achieve a sustained virological response, defined by hepatitis C RNA undetectable in serum 12 weeks after the end of therapy. This indicates viral eradication. Treatment of chronic hepatitis C is a real revolution. New therapies consist in direct acting antivirals. These treatments offer high chance of viral eradication (> 90 %), and are very well tolerated. In Belgium, at the moment, reimbursement of new antiviral therapies is limited to patients with advanced fibrosis or cirrhosis. Those reimbursement criteria would change in a very near future, allowing more patients to be treated. Hepatitis C viral elimination is possible in the next 15 years at a population level in Belgium, but this implies a significant improvement in screening and access to therapy.

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.